A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 22 May 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Registrational
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 20 Jul 2016 Status changed from active, no longer recruiting to completed.
- 23 Jun 2016 Status changed from recruiting to active, no longer recruiting.